Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2

• Introduction: Alzheimer's Disease Neuroimaging Initiative (ADNI) is now in its 10th year. The primary objective of the magnetic resonance imaging (MRI) core of ADNI has been to improve methods for clinical trials in Alzheimer's disease (AD) and related disorders. Methods: We review the contributions of the MRI core from present and past cycles of ADNI (ADNI-1, -Grand Opportunity and -2). We also review plans for the future-ADNI-3. Results: Contributions of the MRI core include creating standardized acquisition protocols and quality control methods; examining the effect of technical features of image acquisition and analysis on outcome metrics; deriving sample size estimates for future trials based on those outcomes; and piloting the potential utility of MR perfusion, diffusion, and functional connectivity measures in multicenter clinical trials. Discussion: Over the past decade the MRI core of ADNI has fulfilled its mandate of improving methods for clinical trials in AD and will continue to do so in the future. (C) 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Nyckelord

Alzheimer's disease

Alzheimer's Disease Neuroimaging Initiative

ADNI

Diffusion

MRI

MILD COGNITIVE IMPAIRMENT

TENSOR-BASED MORPHOMETRY

PREDICT BRAIN

ATROPHY

CSF BIOMARKERS

AMYLOID-BETA

NATIONAL INSTITUTE

ASSOCIATION

WORKGROUPS

DIAGNOSTIC GUIDELINES

CLINICAL-TRIALS

NEURODEGENERATIVE

DISEASE

Clinical Neurology

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)